Topas Therapeutics GmbH

Topas Therapeutics GmbH is a clinical-stage biotechnology company based in Hamburg, Germany, founded in 2006. The company focuses on developing nanoparticle-based therapeutics aimed at establishing immune tolerance for autoimmune and immune-mediated diseases. With a small team of fewer than 25 employees, Topas has reported revenue of $5.9 million and is supported by several investors, including BioMedPartners and Boehringer Ingelheim Venture Fund.

The company's proprietary technology platform, Topas Particle Conjugates (TPC), utilizes engineered nano-sized particles to deliver disease-related peptide epitopes specifically to liver sinusoidal endothelial cells. This approach aims to induce antigen-specific immune tolerance without compromising the overall immune status of patients. Topas is advancing its lead program, TPM502, into a global Phase 2b clinical trial for celiac disease, following promising Phase 2a results. Additionally, the company is conducting clinical testing for TPM203 in pemphigus vulgaris and has several preclinical programs targeting conditions such as type 1 diabetes and rheumatoid arthritis.